BRIEF published on 02/20/2026 at 21:42, 4 months 7 days ago Teva's Olanzapine Injectable Suspension Gains FDA Nod Schizophrenia Olanzapine Teva Pharmaceuticals FDA Acceptance Long-acting Injectable
PRESS RELEASE published on 02/20/2026 at 21:37, 4 months 7 days ago Informations privilégiées / Autres communiqués La FDA américaine accepte le dossier de demande de mise sur le marché de l'Olanzapine LAI par Teva pour le traitement de la schizophrénie chez l'adulte. Une nouvelle option thérapeutique innovante pourrait bientôt être disponible FDA Schizophrénie Traitement Teva Olanzapine LAI
PRESS RELEASE published on 02/20/2026 at 21:37, 4 months 7 days ago Inside Information / Other news releases FDA accepts Teva's NDA for once-monthly olanzapine for schizophrenia treatment, addressing treatment gap. Teva and Medincell collaborate for innovative solution FDA Schizophrenia Medincell Olanzapine Teva
BRIEF published on 02/19/2026 at 10:33, 4 months 8 days ago Franchissement de seuil par Mirova chez MEDINCELL Euronext Paris Droits De Vote Cession D'actions Medincell Mirova
BRIEF published on 02/19/2026 at 10:33, 4 months 8 days ago Mirova crosses a threshold at MEDINCELL Euronext Paris Voting Rights Transfer Of Shares Mirova MEDICELL
PRESS RELEASE published on 02/19/2026 at 10:28, 4 months 8 days ago Franchissement de seuil Déclaration de franchissement de seuil de la société MedinCell par Mirova. Baisse à 6,44% du capital et 4,89% des droits de vote Franchissement De Seuil AMF Baisse Medincell Mirova
BRIEF published on 12/09/2025 at 14:55, 6 months 18 days ago Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI FDA Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 6 months 18 days ago Medincell et Teva soumettent une demande d'autorisation de mise sur le marché auprès de la FDA pour un nouveau traitement injectable. Traitement De La Schizophrénie Medincell Soumission À La FDA Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 6 months 18 days ago Teva Pharmaceuticals soumet une demande d'autorisation pour Olanzapine LAI FDA Schizophrénie Medincell Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 6 months 18 days ago Medincell and Teva Submit FDA Application for New Injectable Treatment Schizophrenia Treatment Medincell FDA Submission Teva Pharmaceuticals Olanzapine LAI
Published on 06/27/2026 at 16:50, 15 hours 22 minutes ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 1 day 6 hours ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 1 day 8 hours ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 day 9 hours ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 day 9 hours ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 1 day 8 hours ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 1 day 8 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 8 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 8 hours ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 1 day 8 hours ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
